• Drug: Pyzchiva (ustekinumab-ttwe)
  • Manufacturer: Sandoz

  • Route of Administration: Intravenous, Subcutaneous

  • Site of Care: Outpatient
  • Approved Indication:

    • treatment of adults and pediatric patients 6 years and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy
    • treatment of active psoriatic arthritis in adults and pediatric patients 6 years and older
    • treatment of moderately-to-severely active Crohn’s disease in adults
    • treatment of moderately-to-severely active ulcerative colitis in adults

  • Disease: Crohn’s disease, plaque psoriasis, psoriatic arthritis, ulcerative colitis

  • Therapeutic Area: Gastroenterology, Rheumatology, Dermatology

  • Enrollment Form Link: Sandoz One Source
  • Phone Number: N/A

  • Fax Number: N/A

  • Product Website: pyzchiva.com